Acadian Asset Management LLC grew its position in shares of Health Catalyst, Inc. (NASDAQ:HCAT - Free Report) by 88.8% during the first quarter, according to its most recent filing with the SEC. The firm owned 930,229 shares of the company's stock after acquiring an additional 437,536 shares during the period. Acadian Asset Management LLC owned about 1.34% of Health Catalyst worth $4,211,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in HCAT. Northern Trust Corp grew its holdings in shares of Health Catalyst by 8.5% during the 4th quarter. Northern Trust Corp now owns 526,607 shares of the company's stock worth $3,723,000 after acquiring an additional 41,298 shares during the period. BNP Paribas Financial Markets bought a new stake in shares of Health Catalyst in the 4th quarter worth approximately $735,000. Deutsche Bank AG boosted its position in shares of Health Catalyst by 9.5% in the 4th quarter. Deutsche Bank AG now owns 225,768 shares of the company's stock worth $1,596,000 after purchasing an additional 19,659 shares in the last quarter. Group One Trading LLC boosted its position in shares of Health Catalyst by 107.6% in the 4th quarter. Group One Trading LLC now owns 4,360 shares of the company's stock worth $31,000 after purchasing an additional 2,260 shares in the last quarter. Finally, ProShare Advisors LLC boosted its position in shares of Health Catalyst by 52.7% in the 4th quarter. ProShare Advisors LLC now owns 16,854 shares of the company's stock worth $119,000 after purchasing an additional 5,815 shares in the last quarter. Hedge funds and other institutional investors own 85.00% of the company's stock.
Wall Street Analyst Weigh In
HCAT has been the topic of a number of analyst reports. Piper Sandler cut Health Catalyst from an "overweight" rating to a "neutral" rating and dropped their price target for the stock from $8.00 to $4.00 in a research report on Wednesday, August 27th. BTIG Research reissued a "neutral" rating on shares of Health Catalyst in a research report on Friday, September 5th. Canaccord Genuity Group dropped their price target on Health Catalyst from $9.00 to $5.00 and set a "buy" rating on the stock in a research report on Friday, August 29th. Evercore ISI boosted their price target on Health Catalyst from $3.00 to $4.00 and gave the stock an "in-line" rating in a research report on Thursday, August 28th. Finally, Wells Fargo & Company dropped their price target on Health Catalyst from $10.00 to $6.00 and set an "overweight" rating on the stock in a research report on Monday, August 11th. Three research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat.com, Health Catalyst presently has an average rating of "Hold" and an average price target of $4.73.
Check Out Our Latest Research Report on Health Catalyst
Health Catalyst Stock Down 4.3%
HCAT stock traded down $0.13 during midday trading on Friday, hitting $2.89. The company's stock had a trading volume of 878,274 shares, compared to its average volume of 817,110. The company has a market cap of $203.37 million, a PE ratio of -1.91 and a beta of 1.53. Health Catalyst, Inc. has a 12 month low of $2.52 and a 12 month high of $9.24. The company has a current ratio of 1.83, a quick ratio of 1.83 and a debt-to-equity ratio of 0.44. The firm's 50-day moving average is $3.41 and its 200-day moving average is $3.81.
Health Catalyst Profile
(
Free Report)
Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.
Read More

Before you consider Health Catalyst, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Health Catalyst wasn't on the list.
While Health Catalyst currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.